InNexus Biotechnology (InNexus Biotechnology) EBIT per Share : $-0.02 (TTM As of Mar. 2011)

View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology EBIT per Share?

InNexus Biotechnology's EBIT per Share for the three months ended in Mar. 2011 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2011 was $-0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for InNexus Biotechnology's EBIT per Share or its related term are showing as below:

IXSBF's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

InNexus Biotechnology's EBIT for the three months ended in Mar. 2011 was $-0.32 Mil.

InNexus Biotechnology EBIT per Share Historical Data

The historical data trend for InNexus Biotechnology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology EBIT per Share Chart

InNexus Biotechnology Annual Data

Trend

Jun01

Jun02

Jun03

Jun04

Jun05

Jun06

Jun07

Jun08

Jun09

Jun10

EBIT per Share

Get a 7-Day Free Trial

-0.10

-0.12

-0.10

-0.08

-0.04

InNexus Biotechnology Quarterly Data
	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.01	-	-	-

InNexus Biotechnology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

InNexus Biotechnology's EBIT per Share for the fiscal year that ended in Jun. 2010 is calculated as

	EBIT per Share		(A: Jun. 2010 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.788	/	96.337
=	-0.04

InNexus Biotechnology's EBIT per Share for the quarter that ended in Mar. 2011 is calculated as

	EBIT per Share		(Q: Mar. 2011 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.316	/	163.448
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

InNexus Biotechnology (GREY:IXSBF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

InNexus Biotechnology EBIT per Share Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

InNexus Biotechnology (InNexus Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7

Website

http://www.ixsbio.com

InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines